This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (38)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Drug Therapy  • Adherence  • Drug Therapy, Other  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Promises and Problems

Paul A. Volberding, MD; Steven G. Deeks, MD

JAMA. 1998;279:1343-1344.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

ALTHOUGH progress against the human immunodeficiency virus (HIV) over the past year has been real and dramatic, the limitations of current antiretroviral therapy are now beginning to be appreciated. In this brief assessment of HIV treatment, we focus on recent advances in antiretroviral therapy, new insights into the pathogenesis of HIV disease, and the implications for clinical practice.

Early Treatment of Acute Infection

In 1996, scientists began to explore the feasibility of HIV eradication in infected patients. This provocative speculation was based on the assumption that cellular reservoirs of HIV have a short half-life and that they are reached by current drugs. Theoretically, if aggressive interventions could completely prevent de novo infection of cells, then therapy could be safely discontinued after all currently infected cells had died. Mathematical models predicted that this goal could be achieved in 1 to 3 years, especially for patients who initiated therapy . . . [Full Text of this Article]

Treatment of Chronic HIV Infection

Limitations and Barriers

From the University of California, San Francisco, and San Francisco General Hospital.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Contempo New and Now: Updates Linking Evidence and Experience
Ronna Henry Siegel
JAMA. 1998;279(17):1395-1396.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Combined Effect of Antiretroviral Therapy and Blockade of IDO in SIV-Infected Rhesus Macaques
Boasso et al.
J. Immunol. 2009;182:4313-4320.
ABSTRACT | FULL TEXT  

Incorporating Pharmakon: HIV, Medicine, and Body Shape Change
Persson
Body Society 2004;10:45-67.
ABSTRACT  

Discordant Outcomes following Failure of Antiretroviral Therapy Are Associated with Substantial Differences in Human Immunodeficiency Virus-Specific Cellular Immunity
Price et al.
J. Virol. 2003;77:6041-6049.
ABSTRACT | FULL TEXT  

Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus Type 1-Infected Children: Analysis of Cellular Immune Responses
Blazevic et al.
CVI 2001;8:943-948.
ABSTRACT | FULL TEXT  

Circulating Metabolites of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir in Humans: Structural Identification, Levels in Plasma, and Antiviral Activities
Zhang et al.
Antimicrob. Agents Chemother. 2001;45:1086-1093.
ABSTRACT | FULL TEXT  

Drug Monitoring of Antiretroviral Therapy for HIV-1 Infection: Method Validation and Results of a Pilot Study
Moyer et al.
Clin. Chem. 1999;45:1465-1476.
ABSTRACT | FULL TEXT  

Deficient Cellular Immunity--Finding and Fixing the Defects
Greenberg and Riddell
Science 1999;285:546-551.
ABSTRACT | FULL TEXT  

Treatments for Wasting in Patients with the Acquired Immunodeficiency Syndrome
Corcoran and Grinspoon
NEJM 1999;340:1740-1750.
FULL TEXT  

Reconsidering targeted toxins to eliminate HIV infection: You gotta have HAART
Berger et al.
Proc. Natl. Acad. Sci. USA 1998;95:11511-11513.
ABSTRACT | FULL TEXT  

Treat HIV-1 Infection Like Other Infections--Treat It
Walker and Basgoz
JAMA 1998;280:91-93.
FULL TEXT  

Contempo New and Now: Updates Linking Evidence and Experience
Siegel
JAMA 1998;279:1395-1396.
FULL TEXT